Search research articles
Contact Us
Filters
Showing results (501-510 of 532) with videos related to
Page
of 54
Sort By:
The Journal of Clinical Endocrinology and Metabolism
|
February 6, 2023
Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study
Karol Mateusz Pencina, Rodrigo Valderrabano, Benjamin Wipper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2012
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer
Edward H Romond, Jong-Hyeon Jeong, Priya Rastogi, et al.
The New England Journal of Medicine
|
January 27, 2012
Bevacizumab added to neoadjuvant chemotherapy for breast cancer
Harry D Bear, Gong Tang, Priya Rastogi, et al.
Breast Cancer Research and Treatment
|
September 3, 2020
Risk factors for inflammatory and non-inflammatory breast cancer in North Africa
Catherine Schairer, Ahmed Hablas, Ibrahim AbdelBar Seif Eldein, et al.
The Lancet. Oncology
|
June 19, 2012
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial
Alexander H G Paterson, Stewart J Anderson, Barry C Lembersky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2021
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study
Ian E Krop, Seock-Ah Im, Carlos Barrios, et al.
Obesity Surgery
|
September 8, 2012
The EMPOWER study: randomized, prospective, double-blind, multicenter trial of vagal blockade to induce weight loss in morbid obesity
Michael G Sarr, Charles J Billington, Roy Brancatisano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2024
Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology])
Charles E Geyer, Joanne L Blum, Greg Yothers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2024
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)
A Fernandez-Martinez, M Tanioka, S G Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 27, 2017
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2
Patricia A Ganz, Edward H Romond, Reena S Cecchini, et al.
Page
of 54
Search research articles
Search
Showing results (501-510 of 532) with videos related to
Sort By:
Page
of 54
The Journal of Clinical Endocrinology and Metabolism
|
February 6, 2023
Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study
Karol Mateusz Pencina, Rodrigo Valderrabano, Benjamin Wipper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2012
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer
Edward H Romond, Jong-Hyeon Jeong, Priya Rastogi, et al.
The New England Journal of Medicine
|
January 27, 2012
Bevacizumab added to neoadjuvant chemotherapy for breast cancer
Harry D Bear, Gong Tang, Priya Rastogi, et al.
Breast Cancer Research and Treatment
|
September 3, 2020
Risk factors for inflammatory and non-inflammatory breast cancer in North Africa
Catherine Schairer, Ahmed Hablas, Ibrahim AbdelBar Seif Eldein, et al.
The Lancet. Oncology
|
June 19, 2012
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial
Alexander H G Paterson, Stewart J Anderson, Barry C Lembersky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2021
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study
Ian E Krop, Seock-Ah Im, Carlos Barrios, et al.
Obesity Surgery
|
September 8, 2012
The EMPOWER study: randomized, prospective, double-blind, multicenter trial of vagal blockade to induce weight loss in morbid obesity
Michael G Sarr, Charles J Billington, Roy Brancatisano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2024
Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology])
Charles E Geyer, Joanne L Blum, Greg Yothers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2024
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)
A Fernandez-Martinez, M Tanioka, S G Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 27, 2017
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2
Patricia A Ganz, Edward H Romond, Reena S Cecchini, et al.
Page
of 54